EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Percutaneous Transcatheter Edge‐to‐Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials With Reconstructed Time‐to‐Event Data

Ramy Ghaly iD, Ahmed Mazen Amin, Samuel Kim, Hosam I Taha iD, Mohamed S Elgendy, Anan Abu Rmilah, Mohamed Abuelazm, Mirza S Khan iD

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31629 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Ramy Ghaly und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Missouri-Kansas City, Kansas City, Missouri, USA. Hauptthemen laut MEDLINE: Heart Failure, Mitral Valve Insufficiency, Cardiac Catheterization, Mitral Valve. Die Arbeit nennt 31 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mitral transcatheter edge‐to‐edge repair (TEER) is approved for patients with severe functional mitral regurgitation (FMR) beyond optimal medical therapy (OMT).

Aims

We aimed to assess TEER's efficacy beyond OMT in patients with severe FMR.

Methods

A systematic review and meta‐analysis were conducted, including randomized controlled trials from PubMed, Cochrane, Scopus, and EMBASE up to September 2024. Primary outcome: heart failure hospitalization (HFH); secondary outcomes: cardiovascular (CV) mortality, all‐cause mortality, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. Time‐to‐event data from Kaplan−Meier curves were reconstructed for individual patient data.

Results

Three studies (1423 patients) were included. TEER significantly reduced HFH (RR 0.73, 95% CI 0.58−0.92, p < 0.01) and CV mortality (RR 0.79, 95% CI 0.66−0.95, p = 0.01), and improved KCCQ scores (mean difference 14.32, 95% CI 10.85−17.80, p < 0.01) compared to OMT. No significant difference was found for all‐cause mortality (RR 0.80, 95% CI 0.63−1.02, p = 0.07). Prognostic meta‐analysis showed a 34% reduced risk of HFH (HR 0.66, 95% CI 0.45−0.96, p = 0.03), but no effect on all‐cause or CV mortality. Reconstructed Kaplan−Meier analysis confirmed a 34% reduced risk of HFH (HR 0.65, p < 0.001), with effect attenuation after 15 months in landmark analysis (HR 0.64, p = 0.07). RMST analysis showed a 2.9‐month longer HFH‐free survival with TEER ( p < 0.01).

Conclusion

In patients with FMR, TEER significantly reduces HFH, improves functional status, and lowers CV mortality at 24 months but does not significantly affect all‐cause mortality. The device group experienced a modest, but significant, 2.9‐month longer HFH‐free survival compared to the control group. However, the reduction in HFH showed attenuation beyond 15 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureMitral Valve InsufficiencyCardiac CatheterizationMitral ValveHeart Valve Prosthesis ImplantationHumansRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeRisk FactorsMaleRecovery of FunctionAgedFemaleRisk AssessmentSeverity of Illness IndexAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

functional mitral regurgitationheart failuretranscatheter edge‐to‐edge repair

Autor:innen und Institutionen

  • University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
  • Faculty of Medicine, Mansoura University, Mansoura, Egypt.
  • Faculty of Medicine, Tanta University, Tanta, Egypt.
  • Internal Medicine Department, Magnolia Regional Health Center, Corinth, Mississippi, USA.
  • Cardiology Department, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Ramy Ghaly, Hosam I Taha, Mirza S Khan

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Ghaly, R., Amin, A. M., Kim, S., Taha, H. I., Elgendy, M. S., Rmilah, A. A., Abuelazm, M., & Khan, M. S. (2025). Percutaneous Transcatheter Edge‐to‐Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials With Reconstructed Time‐to‐Event Data. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31629

Vancouver

Ghaly R, Amin AM, Kim S, Taha HI, Elgendy MS, Rmilah AA, et al. Percutaneous Transcatheter Edge‐to‐Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials With Reconstructed Time‐to‐Event Data. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31629

BibTeX
@article{Ghaly2025,
  author = {Ghaly, Ramy and Amin, Ahmed Mazen and Kim, Samuel and Taha, Hosam I and Elgendy, Mohamed S and Rmilah, Anan Abu and Abuelazm, Mohamed and Khan, Mirza S},
  title = {Percutaneous Transcatheter Edge‐to‐Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials With Reconstructed Time‐to‐Event Data},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31629}
}
Kostenlos starten →